Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9433
Title: Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist.
Austin Authors: Jackman, Graham P;Iakovidis, Dimitri;Nero, Tracy L;Anavekar, Nagesh S;Rezmann-Vitti, Linda A;Louis, Simon N S;Mori, Masanori;Drummer, Olaf H;Louis, William J 
Affiliation: Clinical Pharmacology and Therapeutics Unit, Department of Medicine, Austin and Repatriation Medical Centre, The University of Melbourne, Heidelberg, Vic 3084, Australia
Issue Date: 1-Sep-2002
Publication information: European Journal of Medicinal Chemistry; 37(9): 731-41
Abstract: The synthesis of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride (D140S.HCl 6), a novel short acting beta(1)-specific adrenoceptor antagonist, has been described. The antagonist potency for D140S.HCl 6 has been compared with esmolol, another short acting agent, and other well known beta-adrenoceptor antagonists in isolated rat tissue preparations. The pharmacokinetics of D140S.HCl 6 in 7 day continuous intravenous infusions and 4 weeks intravenous bolus injection studies in conscious rats and dogs have been examined in toxicology studies. The effect on the isoprenaline-induced heart rate increase and the pharmacodynamic half-life of D140S.HCl 6 has been compared with esmolol in a conscious rat model. In addition, the results of a range of toxicological studies are presented. The results indicate that D140S.HCl 6 is a highly specific beta(1)-adrenoceptor antagonist (pA(2) = 8.15+/-0.22, beta(1)/beta(2) selectivity > 4400). The in vitro studies suggest D140S.HCl is ca. ten times more potent and 60 times more beta(1)-specific than racemic esmolol. Pharmacokinetic non-linearity was seen when given as a 7 day intravenous infusion at toxicological doses above 10 mg kg(-1) h(-1) in the rat and 2.5 mg kg(-1) h(-1) in the dog. Both D140S.HCl 6 and esmolol have very short durations of action after intravenous infusion in the rat (pharmacodynamic half-life is < 15 min for D140S.HCl and 10 min for esmolol). The toxicological tests indicate that D140S.HCl 6 shows no unexpected toxicity and none of the tissue irritancy problems reported for esmolol formulations.
Gov't Doc #: 12350290
URI: http://ahro.austin.org.au/austinjspui/handle/1/9433
URL: https://pubmed.ncbi.nlm.nih.gov/12350290
Type: Journal Article
Subjects: Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists.chemical synthesis.pharmacology.toxicity
Adrenergic beta-Antagonists.pharmacology
Animals
Atenolol.pharmacology
Chromatography, High Pressure Liquid
Dogs
Female
Half-Life
Heart Atria.drug effects
In Vitro Techniques
Infusions, Intravenous
Magnetic Resonance Spectroscopy
Myocardial Contraction.drug effects
Propane.analogs & derivatives.chemical synthesis.pharmacology
Propanolamines.pharmacology
Rats
Rats, Sprague-Dawley
Trachea.drug effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Nov 30, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.